Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor

Background: Ezetimibe is the first of a new class of antihyperlipidemic agents, the cholesterol-absorption inhibitors. It is indicated for monotherapy or in combination with 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) in patients with primary hypercholesterolemia, in combina...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2003-09, Vol.25 (9), p.2352-2387
Hauptverfasser:	Jeu, LilyAnn, Cheng, Judy W.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Anticholesteremic Agents - administration & dosage Anticholesteremic Agents - pharmacology Anticholesteremic Agents - therapeutic use Atherosclerosis Azetidines - administration & dosage Azetidines - pharmacology Azetidines - therapeutic use Biological and medical sciences Cardiovascular disease Cholesterol cholesterol-absorption inhibitor Clinical Trials as Topic - statistics & numerical data Coronary vessels Disease prevention Drug Administration Schedule Drug Interactions Drug Therapy, Combination Ezetimibe General and cellular metabolism. Vitamins Heart attacks Humans hypercholesterolemia Hypercholesterolemia - drug therapy Hypercholesterolemia - metabolism Lipids Lipoproteins Lipoproteins - blood Margarine Medical sciences Metabolic disorders Metabolites Pharmacology. Drug treatments SCH 58235 sitosterolemia Statins Triglycerides Vein & artery diseases Women
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!